Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial-Reference-Cited by-同舟云学术

Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial

Published:2019-08-15 Issue:1 Volume:17 Page:
ISSN:1741-7015
Container-title:BMC Medicine
language:en
Short-container-title:BMC Med

Author:

Sheridan Rains Luke^ORCID,Marston Louise,Hinton Mark,Marwaha Steven,Craig Thomas,Fowler David,King Michael,Omar Rumana Z.,McCrone Paul,Spencer Jonathan,Taylor Joanne,Colman Sophie,Harder Catherine,Gilbert Eleanor,Randhawa Amie,Labuschagne Kirsty,Jones Charlotte,Stefanidou Theodora,Christoforou Marina,Craig Meghan,Strang John,Weaver Tim,Johnson Sonia

Funder

Health Technology Assessment Programme

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12916-019-1395-5.pdf

Reference44 articles.

1. Barnes TE, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry. 2006;188:237–42.

2. Schoeler T, Monk A, Sami MB, Klamerus E, Foglia E, Brown R, et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiat. 2016;3:215–25.

3. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective followup study. Br J Psychiatry. 2006;189:229–34.